<p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p>

• DOI: 10.2147/ppa.s251812
• Publication Date: 2020-07-02T00:06:37Z
• Authors: Clifton Blackwood; Panna Sanga; Isaac Nuamah; Alexander Keenan; Arun Singh; Maju Mathews; Srihari Gopal
• Keywords: Pill; Post-hoc analysis

Understanding patients' preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia.Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate patients with schizophrenia. Data the Medication Preference Questionnaire, administered on day 1 (baseline; open-label stabilization phase), analyzed. The questionnaire includes four sets items: 1) reasons general treatment preference based goals/outcomes and pills 2) personal experience, 3) injection-site (deltoid gluteal), 4) dosing frequency (3-monthly 1-monthly). A logistic regression analysis was performed assess effect baseline variables (LAIs pills).Data 1402 available analysis. Patients who preferred LAIs recognized these outcomes as important: "I feel more healthy" (57%), can get back my favorite activities" (56%), don't have think about taking medicines" (54%). Most common medication (LAI pills) were: "LAIs/pills are easier me" (67% 18%), "more control/don't medicine" (64% 14%), "less pain/sudden symptoms" (38% 18%) embarrassed" (0% 46%). Majority (59%) deltoid over gluteal injections (reasons: faster administration [63%], [51%], less embarrassing [44%]). In total, 50% (38%) every (3%) citing reasons: fewer [96%], painful [84%], doctor visits [80%]. From analysis, 77% pills; culture race appeared play role this preference.Patients prioritized self-empowerment quality-of-life-related goals. When given option, less-frequent, quarterly monthly daily medications.